We outline a protocol to detect simultaneous expression of leukemia stem cell markers on primary acute myeloid leukemia cells by flow cytometry. We show how to quantify three progenitor populations and a putative LSC population with increasing degree of maturation. We confirmed the presence of these populations in corresponding patient-derived-xenografts.
Acute myeloid leukemia (AML) is a heterogeneous, and if not treated, fatal disease. It is the most common cause of leukemia-associated mortality in adults. Initially, AML is a disease of hematopoietic stem cells (HSC) characterized by arrest of differentiation, subsequent accumulation of leukemia blast cells, and reduced production of functional hematopoietic elements. Heterogeneity extends to the presence of leukemia stem cells (LSC), with this dynamic cell compartment evolving to overcome various selection pressures imposed upon during leukemia progression and treatment. To further define the LSC population, the addition of CD90 and CD45RA allows the discrimination of normal HSCs and multipotent progenitors within the CD34+CD38- cell compartment. Here, we outline a protocol to detect simultaneous expression of several putative LSC markers (CD34, CD38, CD45RA, CD90) on primary blast cells of human AML by multiparametric flow cytometry. Furthermore, we show how to quantify three progenitor populations and a putative LSC population with increasing degree of maturation. We confirmed the presence of these populations in corresponding patient-derived-xenografts. This method of detection and quantification of putative LSC may be used for clinical follow-up of chemotherapy response (i.e., minimal residual disease), as residual LSC may cause AML relapse.
Acute myeloid leukemia (AML) is the most common cause of leukemia-associated mortality. Initially, AML is a clonal disease of hematopoietic stem cells (HSC) characterized by arrest of differentiation, subsequent accumulation of blast cells, and reduced production of functional hematopoietic elements. Recently, clonal heterogeneity of the blast cell population has been established essentially by using next generation sequencing (NGS) strategies and showing the existence of intra-clonal evolution of tumor cells1.
Heterogeneity extends to the presence of leukemic stem cells (LSC). It is hypothesized that this dynamic cell compartment evolves to overcome various selection pressures imposed upon during leukemia progression and treatment. Therefore LSC are supposed to be resistant to current chemotherapeutic regimens and mediate disease relapse, with profound clinical implications2. Various markers have been described to characterize LSC like CD1233, CLL-14, CD975 or TIM-36. The CD34+CD38- compartment of blast cells is considered to be enriched for LSC7 but also includes normal HSC. CD90 and CD45RA expression applied to the CD34+CD38- (P6) compartment (Figure 1) permits to segregate several stages of normal and malignant hematopoietic precursors8. Specifically, normal CD34+CD38-CD90+CD45RA- HSCs, multipotent progenitors (MPP) like CD34+CD38-CD90dimCD45RA- cells and CD34+CD38-CD90-CD45RA+ lymphoid-primed multipotent progenitor (LMPP) cells can be determined in the majority of AML cases8,9. The mean fluorescence intensity (MFI) of CD38 is particularly important to be considered within the CD34+ cell compartment. Because CD38 intensity defines three new cell compartments thereof: CD38 negative (P6), CD38 dim (P7) and CD38 bright (P8) (Figure 1). The MFI of CD38 may be determined using either hematogones and/or plasma cells as an internal positive control as these cells strongly express CD38.
The immunodeficient NOD/SCID/IL2Rγcnull (NSG) mouse model is widely used for engraftment of normal and malignant human hematopoietic cells10,11. Serial xenotransplantation assays are used to experimentally validate LSC or HSC function. These studies have been extensively analyzed by large scale sequencing approaches. Nevertheless, less is known about the LSC and HSC immunophenotype of AML blast population engrafted into NSG mice compared to its primary AML (Figure 2).
The numbers of LSC are inherently low thus, identification and quantification of LSC are challenging and the method described here may be used as a flow cytometric assay at diagnosis and at clinical follow up to evaluate chemotherapy response (as residual LSC may cause AML relapse). The presence of LSC may indicate positive minimal residual disease (MRD). To date, MRD monitoring in AML mostly rely on molecular methods (i.e., RT-PCR, NGS)10,12. However, in this protocol we detect simultaneous protein expression of several HSC/LSC markers (CD34, CD38, CD45RA, CD90) on primary blast cells of human AML by multiparametric flow cytometry2,8,9. This combination of antibodies may be applied in any standard flow cytometry laboratory and this flow MRD assay is particularly interesting when MRD by real-time polymerase chain reaction (RT-PCR) is not possible, i.e., if leukemia specific molecular markers are not detectable in the diagnostic AML sample. Furthermore, this protocol, is complementary to the more sensitive molecular MRD techniques, as it aims to detect and quantify the abnormal hematopoietic progenitor cells which represents a functional cell characteristic (Figure 3).
We show how to quantify three hematopoietic progenitor populations and the putative LSC compartment with different degree of maturation by flow cytometry with antibodies available in the majority of clinical laboratories. Furthermore, we confirmed the presence of these cell compartments in corresponding patient-derived-xenografts (PDX) and at treatment follow up.
We follow European standards for the use of animals for scientific purposes. This study was approved by the local Ethics committee (#3097-2015120414583482v3).
1. Sample preparation
2. Lysis of red blood cells (RBC)
3. Patient derived xenografts.
4. Staining
5. Gating strategy for flow cytometry analysis
6. MRD monitoring by RT-PCR
Here we present a method to determine progenitor populations in normal and malignant human bone marrow samples. We collected bone marrow and spleen from a successful PDX and performed multiparametric flow cytometry as described above. We compared several subpopulations of blast cells between the diagnostic patient sample and the corresponding PDX and particularly, the CD34+CD38- progenitor compartment, notably enriched in putative LSC. We have found that the CD34+CD38- blast fraction was higher in PDX compared to the diagnostic patient sample (3.48% vs. 0.53%, Figure 2C, D). Interestingly, we found a higher percentage of putative LSC (displaying a CD34+CD38-CD90-CD45RA+ phenotype) in the PDX compared to the primary patient sample (2.76% vs. 0.48%, Figure 2E, F), suggesting a possible enrichment of malignant progenitor cells in hematologic tissues in this mouse model. The frequency of normal progenitor cell fractions did not differ between the PDX and the patient sample.
Furthermore, we studied the blast cell progenitor populations based on the expression of CD34, CD38, CD90, and CD45A (as described in this protocol) in two different patient samples, at diagnosis and at treatment follow-up to determine the level of MRD. In the first patient, the CD34+CD38- (P6) fraction increased from 0.06% at diagnosis to 3.33% at the first treatment follow-up (Figure 3A, B). In contrast, the CD34+CD38- (P6) fraction decreased in the second patient from 7.8% at diagnosis to 2.27% at the first treatment follow-up (Figure 3C, D). Accordingly, the putative LSC fraction increased in the first patient from 0% at diagnosis to 0.65% (Figure 3A’, B’) and decreased in the second patient from 6.57% at diagnosis to 1.44% at treatment follow-up (Figure 3C’, D’). Similarly, MRD monitoring by molecular markers (i.e., NPM1 mutation [first patient] and CBFB-MYH11 translocation [second patient]) showed that molecular MRD decrease less in the first patient (0.8%) compared to the second patient (0.05%) for the first treatment follow-up point (Figure 3E, G). Finally, to validate that putative P6 LSC are malignant, expression of leukemia associated antigens CD123 and CD33 were estimated, showing abnormal expression of CD33 for both patients (Figure 3F, G).
Figure 1: Gating strategy used for physiologic precursors and AML blasts. Density plot with gating of physiologic precursors shown for a normal bone marrow. (A) Gating of blast cells based upon CD45dimSSClow phenotype on all mononucleated cells. (B) Gating of hematogones (CD38+CD19+) for verification of CD38 positivity. (C). Gating strategy of normal myeloblasts, monoblasts and erythroblasts based on CD33 and CD36. (D) Blast cells can be separated into CD34+ progenitor subpopulations and using CD38 expression into P6 (CD34+CD38-), P7 (CD34+CD38dim), P8 (CD34+CD38+) cell compartments. (E) Gating of hematogones based on CD34 and CD38 expression, verify CD38 positivity. (G) Determination of HSC, MPP, LMPP, and putative LSC subpopulations using expression of CD90 and CD45RA as previously described9. Of note, no detection of LSC as this is a normal bone marrow sample. Please click here to view a larger version of this figure.
Figure 2: Blast cell progenitor populations in a patient and in corresponding patient-derived-xenograft (PDX) by multiparametric flow cytometry. (A-B) Chimerism analysis of PDX. (A) Murine and human blasts are first defined by size and structure (FSC, SSC). (B) Subsequently, the percentage of human versus murine CD45 staining is indicative of xenoengraftment and leukemia burden. Comparison of CD34+CD38- blast cells percentage between (C) primary diagnostic and (D) PDX AML sample. Comparison of putative LSC (CD34+CD38-CD90-CD45RA+) between (E) primary AML and (F) PDX. Please click here to view a larger version of this figure.
Figure 3: Blast cell progenitor populations in two patients at diagnosis and after remission induction therapy for minimal residual disease (MRD) detection. Flow cytometric analysis of CD34+CD38- blast cell subpopulations in two representative patients (A, C) at diagnosis and (B, D) after remission induction therapy. Figures (A’-D’) illustrate respective P6 gates containing putative LSC for the two patients at diagnosis and after initial treatment. Shown in (E, G) is the minimal residual disease (MRD) analysis by molecular markers used for these two patients over a period of five months (NPM1 mutation and CBFß-MYH11 gene fusion, respectively). (F, G) Expression of leukemia associated antigens CD123 and CD33 on putative P6 LSC, showing abnormal expression of CD33 for both patients. Please click here to view a larger version of this figure.
An accurate and reproducible assessment of membrane or cytoplasmic markers by flow cytometry requires that instrument settings are verified every day for optical alignment, proper functioning of the fluidic system, optical sensitivity, and standardization using calibration beads.
Detection of blast cell populations in AML using CD90 and CD45RA by multi-parametric flow cytometry analysis is a relatively simple and reliable method. A critical step in this analysis is an accurate assessment of CD38 expression on blast cells, in order to perform correct gating of the CD34+CD38- population. CD38 intensity is defined using normal bone marrow cells specifically on hematogones and/or plasma cells (CD38+). Intensity of other markers is determined using isotype controls.
The addition of CD45RA and CD90 is used to distinguish HSC from putative LSC. The latter and not HSC maybe the cause of disease relapse, thus this protocol is of interest for minimal residual disease monitoring using flow cytometry panels. Monitoring of AML during treatment is essential to improve risk stratification and to guide AML therapy. Unfortunately, appropriate molecular markers are not available for all patients. Therefore, MRD monitoring by flow cytometry may be feasible for all AML cases. Even though this method may not be exhaustive as it focalizes on the majority of AML cases which have a CD34+CD38- progenitor and a putative LSC population. Of note, it is possible that the putative LSC compartment may include normal progenitors, i.e., LMPP). Furthermore, we cannot rule out that there are rare cases with functional LSC not following this abnormal expression pattern. Of note, even in NPM1-mutated AML which are considered CD34 negative, we are able to detect putative LSC. Therefore, despite the heterogeneity and complexity of the AML LSC compartment, our method may be used as a biomarker of chemotherapy response during follow up of AML.
The authors have nothing to disclose.
This work was in part supported by the French Association Laurette Fugain, LigueContre le Cancer (North Center), Fondation de France (Leukemia Committee), SIRIC Oncolille, and French National Cancer Institute.
Pancoll | PAN-Biotech | P04-60500 | |
RBC Lysis Buffer (10x) | Ozyme | BLE420301 | RBC Lysis solution A : 8.29 g of NH4Cl + 0.037 g of Na2EDTA in 100 mL of sterile H2O and RBC Lysis solution B: 1 g of KHCO3 in 100 mL of sterile H2O |
NOD/SCID/IL2Rγcnull (NSG) mice | JACKSON LABORATORY | Stock No: 005557 | |
PBS | Gibco by life technologies | 14190-144 | |
AutoMACS Running Buffer – MACS Separation Buffer | MACS Buffer Miltenybiotec | 130-091-221 | |
Anti-CD36-FITC (clone FA6-152, Iotest) | Beckman Coulter | PN IM0766U | |
Anti-CD33-PC5.5 (clone D3HL60.251, Iotest) | Beckman Coulter | B36289 | |
Anti-CD90-APC (clone 5E10) | Biolegend | 328114 | |
Anti-CD19-ECD (clone J3-119, Iotest) | Beckman Coulter | A07770 | |
Anti-CD34-AA700 (clone 581, Iotest) | Beckman Coulter | B92417 | |
Anti-CD45RA-APC-H7 (clone HI100) | Beckton Dickinson | 560674 | |
Anti-CD38-Pacific Blue (clone LSI98-4-3, Iotest) | Beckman Coulter | B92396 | |
Anti-CD45-KO (clone J.33, Iotest) | Beckman Coulter | B36294 | |
Anti-CD3-PE | Beckman Coulter | IM1451 | |
Anti-CD20-PE | Beckman Coulter | A07747 | |
Anti-CD123-PC7 | Beckman Coulter | B13647 | |
Flow-Set | Beckman Coulter | A63492 | |
Flow-Check | Beckman Coulter | A63493 | |
Navios | Beckman Coulter | DS-14644A | |
LSR Fortessa X20 | BD Biosciences | ||
CST BD | BD Biosciences | 655051 | |
FacsFlow | BD Biosciences | 336911 | |
Anti-hCD45-FITC | Biolegend | BLE304006 | |
Anti-mCD45-APC | Biolegend | BLE103112 | |
EasySep human PE selection kit | Stem Cell Technologies | 18000 | |
EasySep magnet | Stem Cell Technologies | 18551 |